Johnson & Johnson Hits New High Amid Growing Pharmaceutical and MedTech Strength

Johnson & Johnson (NYSE:JNJ) has reached a new 12-month high of $275.53 during mid-day trading on Wednesday, exceeding its previous closing price of $271.11.

The company's robotic-surgery opportunity has expanded with FDA clearance for its AI-powered MONARCH QUEST 3 bronchoscopy update, which adds enhanced planning, navigation, imaging, and procedure-review capabilities.

In addition to the robotic-surgery news, Johnson & Johnson's recent financial performance exceeded expectations, with a 6.6% year-over-year increase in second-quarter revenue to $25.31 billion, beating the consensus estimate of $25.06 billion.